{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:01:18Z","timestamp":1791421278867,"version":"4.3.3"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40265-025-02262-1","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T19:32:23Z","timestamp":1764099143000},"page":"59-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pan-JAK Inhibition Across Chronic Hand Eczema and Other Cutaneous Diseases: An Updated Review on Topical Delgocitinib"],"prefix":"10.1007","volume":"86","author":[{"given":"Davide","family":"Termini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7253-2370","authenticated-orcid":false,"given":"Gianluca","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tavoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Beaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Moltrasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Boero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"5","key":"2262_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova-Fischer I, Arents BWM, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357\u201378. https:\/\/doi.org\/10.1111\/cod.14035.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"2262_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40257-015-0130-z","volume":"16","author":"D Antonov","year":"2015","unstructured":"Antonov D, Schliemann S, Elsner P. Hand dermatitis: a review of clinical features, prevention and treatment. Am J Clin Dermatol. 2015;16(3):247\u201357. https:\/\/doi.org\/10.1007\/s40257-015-0130-z.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"2262_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40257-024-00890-z","volume":"25","author":"E Weisshaar","year":"2024","unstructured":"Weisshaar E. Chronic hand eczema. Am J Clin Dermatol. 2024;25(6):909\u201326. https:\/\/doi.org\/10.1007\/s40257-024-00890-z.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"2262_CR4","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.jaad.2024.09.048","volume":"93","author":"R Bissonnette","year":"2025","unstructured":"Bissonnette R, Agner T, Molin S, Guttman-Yassky E. Hand eczema. Part 1: epidemiology, pathogenesis, diagnosis and work-up. J Am Acad Dermatol. 2025;93(5):1201\u201310. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.048.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2262_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ddg.12510_1","volume":"13","author":"TL Diepgen","year":"2015","unstructured":"Diepgen TL, Andersen KE, Chosidow O, Coenraads PJ, Elsner P, English J, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. JDDG J Dtsch Dermatol Ges. 2015;13(1):e1-22. https:\/\/doi.org\/10.1111\/ddg.12510_1.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"8","key":"2262_CR6","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1111\/all.16466","volume":"80","author":"J Bar","year":"2025","unstructured":"Bar J, Del Duca E, David E, Bose S, Chefitz G, Brunner PM, et al. Skin tape stripping reveals distinct biomarker profiles in chronic hand eczema of patients with and without comorbid atopic dermatitis. Allergy. 2025;80(8):2271\u201385. https:\/\/doi.org\/10.1111\/all.16466.","journal-title":"Allergy"},{"issue":"6","key":"2262_CR7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/bjd\/ljaf020","volume":"192","author":"C Apfelbacher","year":"2025","unstructured":"Apfelbacher C, Bewley A, Molin S, Fargnoli MC, Gim\u00e9nez-Arnau AM, Brignoli L, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60,000 respondents in the general population in Canada, France, Germany, Italy, Spain, and the United Kingdom. Br J Dermatol. 2025;192(6):1047\u201354. https:\/\/doi.org\/10.1093\/bjd\/ljaf020. (19).","journal-title":"Br J Dermatol"},{"issue":"1","key":"2262_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jdv.16061","volume":"34","author":"T Agner","year":"2020","unstructured":"Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol. 2020;34(1):4\u201312. https:\/\/doi.org\/10.1111\/jdv.16061.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2262_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/cod.12130","volume":"39","author":"PA Cortesi","year":"2014","unstructured":"Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Clin Exp Dermatol. 2014;39(1):16\u201322. https:\/\/doi.org\/10.1111\/cod.12130.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"2262_CR10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/jdv.13479","volume":"30","author":"S Cazzaniga","year":"2016","unstructured":"Cazzaniga S, Ballmer-Weber BK, Gr\u00e4ni N, Spring P, Bircher A, Anliker M, et al. Medical, psychological and socio-economic implications of chronic hand eczema: a cross-sectional study. J Eur Acad Dermatol Venereol. 2016;30(4):628\u201337. https:\/\/doi.org\/10.1111\/jdv.13479.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2262_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/DER.0000000000000598","volume":"31","author":"S Capucci","year":"2020","unstructured":"Capucci S, Hahn-Pedersen J, Vilsb\u00f8ll A, Kragh N. Impact of atopic dermatitis and chronic hand eczema on quality of life compared with other chronic diseases. Dermatitis. 2020;31(3):178\u201384. https:\/\/doi.org\/10.1097\/DER.0000000000000598.","journal-title":"Dermatitis"},{"issue":"3","key":"2262_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40257-021-00669-6","volume":"23","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, et al. Economic burden of chronic hand eczema: a review. Am J Clin Dermatol. 2022;23(3):287\u2013300. https:\/\/doi.org\/10.1007\/s40257-021-00669-6.","journal-title":"Am J Clin Dermatol"},{"key":"2262_CR13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2147\/TCRM.S292504","volume":"16","author":"C Dubin","year":"2020","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319\u201332. https:\/\/doi.org\/10.2147\/TCRM.S292504.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"2262_CR14","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.jaad.2024.09.049","volume":"93","author":"R Bissonnette","year":"2025","unstructured":"Bissonnette R, Agner T, Taylor JS, Molin S, Guttman-Yassky E. Hand eczema. Part 2: prevention, management, and treatment. J Am Acad Dermatol. 2025;93(5):1213\u201324. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.049.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2262_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/DER.0000000000000659","volume":"32","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Guttman-Yassky E, Agner T, Bissonnette R, Cohen DE, Simpson E, et al. Chronic hand eczema guidelines from an expert panel of the International Eczema Council. Dermatitis. 2021;32(5):319\u201326. https:\/\/doi.org\/10.1097\/DER.0000000000000659.","journal-title":"Dermatitis"},{"issue":"5","key":"2262_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ad.2015.04.005","volume":"106","author":"FJ de Le\u00f3n","year":"2015","unstructured":"de Le\u00f3n FJ, Berbegal L, Silvestre JF. Management of chronic hand eczema. Actas Dermosifiliogr. 2015;106(5):362\u201370. https:\/\/doi.org\/10.1016\/j.ad.2015.04.005.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"2262_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","volume":"54","author":"UR Hengge","year":"2006","unstructured":"Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1\u201315. https:\/\/doi.org\/10.1016\/j.jaad.2005.01.010.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2262_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.268","volume":"3","author":"J Harvey","year":"2023","unstructured":"Harvey J, Lax SJ, Lowe A, et al. The long-term safety of topical corticosteroids in atopic dermatitis: a systematic review. Skin Health Dis. 2023;3(4):e268. https:\/\/doi.org\/10.1002\/ski2.268.","journal-title":"Skin Health Dis"},{"issue":"4 Suppl. 1","key":"2262_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.12.330","volume":"68","author":"A Tammaro","year":"2013","unstructured":"Tammaro A, D\u2019Erme AM, De Marco G, Gola M, Milanesi N, Persechino S. Alitretinoin: a new systemic treatment in the management of chronic hand eczema. J Am Acad Dermatol. 2013;68(4 Suppl. 1):AB79. https:\/\/doi.org\/10.1016\/j.jaad.2012.12.330.","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"2262_CR20","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40265-016-0621-0","volume":"76","author":"HA Blair","year":"2016","unstructured":"Blair HA, Scott LJ. Alitretinoin: a review in severe chronic hand eczema. Drugs. 2016;76(13):1271\u20139. https:\/\/doi.org\/10.1007\/s40265-016-0621-0.","journal-title":"Drugs"},{"issue":"4","key":"2262_CR21","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1365-2133.2008.08487.x","volume":"158","author":"T Ruzicka","year":"2008","unstructured":"Ruzicka T, Lynde CW, Jemec GBE, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158(4):808\u201317. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08487.x.","journal-title":"Br J Dermatol"},{"key":"2262_CR22","unstructured":"European Medicines Agency (EMA). Anzupgo: EPAR: medicine overview. Published September 24, 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/anzupgo. Accessed 17 Nov 2025."},{"issue":"12","key":"2262_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1358\/dot.2021.57.12.3352760","volume":"57","author":"J Ho","year":"2021","unstructured":"Ho J, Molin S. Delgocitinib in atopic dermatitis. Drugs Today. 2021;57(12):719\u201331. https:\/\/doi.org\/10.1358\/dot.2021.57.12.3352760.","journal-title":"Drugs Today"},{"issue":"6","key":"2262_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40265-020-01291-2","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Delgocitinib: first approval. Drugs. 2020;80(6):625\u20139. https:\/\/doi.org\/10.1007\/s40265-020-01291-2.","journal-title":"Drugs"},{"issue":"1","key":"2262_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","volume":"64","author":"A Tanimoto","year":"2015","unstructured":"Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64(1):41\u201351. https:\/\/doi.org\/10.1007\/s00011-014-0782-9.","journal-title":"Inflamm Res"},{"issue":"6","key":"2262_CR26","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","volume":"152","author":"DK Chu","year":"2023","unstructured":"Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nu\u00f1ez JJ, Gomez-Escobar L, et al. Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1493\u2013519. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.030.","journal-title":"J Allergy Clin Immunol"},{"key":"2262_CR27","unstructured":"ClinicalTrials.gov. Pharmacokinetics of delgocitinib 20 mg\/g cream in subjects with chronic hand eczema. ClinicalTrials.gov identifier: NCT05486117. Posted April 4, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05486117. Accessed 24 Apr 2025."},{"issue":"3","key":"2262_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2479126","volume":"36","author":"A Abdelhalim","year":"2025","unstructured":"Abdelhalim A, et al. Topical delgocitinib for the treatment of chronic hand eczema. J Dermatolog Treat. 2025;36(3):e2479126. https:\/\/doi.org\/10.1080\/09546634.2025.2479126.","journal-title":"J Dermatolog Treat"},{"key":"2262_CR29","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of delgocitinib cream in adult participants with moderate to severe chronic hand eczema (DELTA 1). Identifier: NCT04871711. https:\/\/clinicaltrials.gov\/study\/NCT04871711. Accessed 17 Nov 2025."},{"key":"2262_CR30","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of delgocitinib cream in adult participants with moderate to severe chronic hand eczema (DELTA 2). Identifier: NCT04872101. https:\/\/clinicaltrials.gov\/study\/NCT04872101. Accessed 17 Nov 2025."},{"issue":"10451","key":"2262_CR31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404(10451):461\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(24)01027-4.","journal-title":"Lancet"},{"key":"2262_CR32","unstructured":"ClinicalTrials.gov. Open-label multi-site extension trial in subjects who completed the DELTA 1 or DELTA 2 trials (DELTA 3). ClinicalTrials.gov identifier: NCT04949841. https:\/\/clinicaltrials.gov\/study\/NCT04949841. Accessed 24 Apr 2025."},{"issue":"1","key":"2262_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2025.03.008","volume":"93","author":"M Gooderham","year":"2025","unstructured":"Gooderham M, Molin S, Bissonnette R, Worm M, Cr\u00e9py M-N, Stingeni L, et al. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol. 2025;93(1):95\u2013103. https:\/\/doi.org\/10.1016\/j.jaad.2025.03.008.","journal-title":"J Am Acad Dermatol"},{"key":"2262_CR34","unstructured":"ClinicalTrials.gov. Delgocitinib cream for the treatment of moderate to severe atopic dermatitis during 8 weeks in adults, adolescents, and children. ClinicalTrials.gov identifier: NCT03826901. Updated March 27, 2024. https:\/\/clinicaltrials.gov\/study\/NCT03826901. Accessed 24 Apr 2025."},{"key":"2262_CR35","unstructured":"ClinicalTrials.gov. Dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg\/g compared to delgocitinib cream vehicle over an 8-week treatment period in adult subjects with atopic dermatitis. ClinicalTrials.gov identifier: NCT03725722. Updated March 27, 2024. https:\/\/clinicaltrials.gov\/study\/NCT03725722. Accessed 24 Apr 2025."},{"issue":"4","key":"2262_CR36","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s13555-019-00329-y","volume":"9","author":"AM Montilla","year":"2019","unstructured":"Montilla AM, G\u00f3mez-Garc\u00eda F, G\u00f3mez-Arias PJ, et al. Scoping review on the use of drugs targeting JAK\/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther (Heidelb). 2019;9(4):655\u201383. https:\/\/doi.org\/10.1007\/s13555-019-00329-y.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"2262_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1365-2133.2008.08907.x","volume":"160","author":"TL Diepgen","year":"2009","unstructured":"Diepgen TL, Andersen KE, Brandao FM, Bruze M, Bruynzeel DP, Frosch P, et al. Hand eczema classification: a cross-sectional, multicentre study of the aetiology and morphology of hand eczema. Br J Dermatol. 2009;160(2):353\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08907.x.","journal-title":"Br J Dermatol"},{"issue":"12","key":"2262_CR38","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1111\/jdv.13308","volume":"29","author":"T Agner","year":"2015","unstructured":"Agner T, Aalto-Korte K, Andersen KE, Foti C, Gimen\u00e9z\u2010Arnau A, Goncalo M, et al. Classification of hand eczema. J Eur Acad Dermatol Venereol. 2015;29(12):2417\u201322. https:\/\/doi.org\/10.1111\/jdv.13308.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"2262_CR39","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaci.2012.06.048","volume":"131","author":"JK Gittler","year":"2013","unstructured":"Gittler JK, Krueger JG, Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol. 2013;131(2):300\u201313. https:\/\/doi.org\/10.1016\/j.jaci.2012.06.048.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2262_CR40","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/bjd.13418","volume":"172","author":"S Molin","year":"2015","unstructured":"Molin S, Merl J, Dietrich KA, Regauer M, Flaig M, Letul\u00e9 V, et al. The hand eczema proteome: imbalance of epidermal barrier proteins. Br J Dermatol. 2015;172(4):994\u20131001. https:\/\/doi.org\/10.1111\/bjd.13418.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2262_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-018-8685-0","volume":"56","author":"A Leonard","year":"2019","unstructured":"Leonard A, Guttman-Yassky E. The unique molecular signatures of contact dermatitis and implications for treatment. Clin Rev Allergy Immunol. 2019;56(1):1\u20138. https:\/\/doi.org\/10.1007\/s12016-018-8685-0.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"2262_CR42","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1111\/jdv.19742","volume":"38","author":"AS Quaade","year":"2024","unstructured":"Quaade AS, Wang X, S\u00f8lberg JBK, et al. Inflammatory plasma signature of chronic hand eczema: associations with aetiological and clinical subtypes. J Eur Acad Dermatol Venereol. 2024;38(1):e23\u20136. https:\/\/doi.org\/10.1111\/jdv.19742.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2262_CR43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1600-0536.2008.01317.x","volume":"58","author":"CM De Jongh","year":"2008","unstructured":"De Jongh CM, John SM, Bruynzeel DP, et al. Cytokine gene polymorphisms and susceptibility to chronic irritant contact dermatitis. Contact Dermatitis. 2008;58(5):269\u201377. https:\/\/doi.org\/10.1111\/j.1600-0536.2008.01317.x.","journal-title":"Contact Dermatitis"},{"issue":"2","key":"2262_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s13671-021-00351-4","volume":"11","author":"K Patel","year":"2022","unstructured":"Patel K, Nixon R. Irritant contact dermatitis: a review. Curr Dermatol Rep. 2022;11(2):41\u201351. https:\/\/doi.org\/10.1007\/s13671-021-00351-4.","journal-title":"Curr Dermatol Rep"},{"key":"2262_CR45","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/916497","volume":"2013","author":"HY Lee","year":"2013","unstructured":"Lee HY, Stieger M, Yawalkar N, Kakeda M. Cytokines and chemokines in irritant contact dermatitis. Mediat Inflamm. 2013;2013:916497. https:\/\/doi.org\/10.1155\/2013\/916497.","journal-title":"Mediat Inflamm"},{"issue":"5 Pt 1","key":"2262_CR46","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/0190-9622(95)91817-5","volume":"33","author":"S Kondo","year":"1995","unstructured":"Kondo S, Sauder DN. Epidermal cytokines in allergic contact dermatitis. J Am Acad Dermatol. 1995;33(5 Pt 1):786\u201396. https:\/\/doi.org\/10.1016\/0190-9622(95)91817-5.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2262_CR47","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jaci.2022.02.002","volume":"149","author":"JD Johansen","year":"2022","unstructured":"Johansen JD, Bonefeld CM, Schwensen JFB, Thyssen JP, Uter W. Novel insights into contact dermatitis. J Allergy Clin Immunol. 2022;149(4):1162\u201371. https:\/\/doi.org\/10.1016\/j.jaci.2022.02.002.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2262_CR48","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","volume":"134","author":"N Dhingra","year":"2014","unstructured":"Dhingra N, Shemer A, da Correa Rosa J, et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol. 2014;134(2):362\u201372. https:\/\/doi.org\/10.1016\/j.jaci.2014.03.009.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2262_CR49","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1600-0625.2012.01471.x","volume":"21","author":"SF Martin","year":"2012","unstructured":"Martin SF. Contact dermatitis: from pathomechanisms to immunotoxicology. Exp Dermatol. 2012;21(5):382\u20139. https:\/\/doi.org\/10.1111\/j.1600-0625.2012.01471.x.","journal-title":"Exp Dermatol"},{"issue":"1","key":"2262_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaci.2006.04.042","volume":"118","author":"MJ Cork","year":"2006","unstructured":"Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol. 2006;118(1):3\u201321. https:\/\/doi.org\/10.1016\/j.jaci.2006.04.042.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2262_CR51","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jaci.2024.12.1091","volume":"155","author":"AS Quaade","year":"2025","unstructured":"Quaade AS, Litman T, Wang X, Becker C, McCauley BD, S\u00f8lberg JBK, et al. Transcriptomic profiling of chronic hand eczema skin reveals shared immune pathways and molecular drivers across subtypes. J Allergy Clin Immunol. 2025;155(4):1250\u201363. https:\/\/doi.org\/10.1016\/j.jaci.2024.12.1091.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2262_CR52","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/bjd\/ljaf020","volume":"192","author":"C Apfelbacher","year":"2025","unstructured":"Apfelbacher C, Bewley A, Molin S, Fargnoli MC, Gim\u00e9nez-Arnau A, Brignoli L, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Br J Dermatol. 2025;192(6):1047\u201354. https:\/\/doi.org\/10.1093\/bjd\/ljaf020.","journal-title":"Br J Dermatol"},{"key":"2262_CR53","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","volume":"10","author":"F Solimani","year":"2019","unstructured":"Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. https:\/\/doi.org\/10.3389\/fimmu.2019.02847.","journal-title":"Front Immunol"},{"issue":"10","key":"2262_CR54","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s00403-024-03502-2","volume":"316","author":"S Raja","year":"2024","unstructured":"Raja S, Raja A, Shuja MH, Ali A. Clinical benefits of delgocitinib cream for chronic hand eczema: a systematic review and meta-analysis. Arch Dermatol Res. 2024;316(10):734. https:\/\/doi.org\/10.1007\/s00403-024-03502-2.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"2262_CR55","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1365-2133.2004.06305.x","volume":"152","author":"E Held","year":"2005","unstructured":"Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema: a study of inter- and intraobserver reliability. Br J Dermatol. 2005;152(2):302\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.06305.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2262_CR56","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/bjd.18295","volume":"181","author":"JAF Oosterhaven","year":"2019","unstructured":"Oosterhaven JAF, Schuttelaar MLA. Responsiveness and interpretability of the hand eczema severity index. Br J Dermatol. 2019;181(4):788\u201394. https:\/\/doi.org\/10.1111\/bjd.18295.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2262_CR57","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s12325-019-01164-5","volume":"37","author":"L Grant","year":"2020","unstructured":"Grant L, Larsen LS, Burrows K, et al. Development of a conceptual model of chronic hand eczema (CHE) based on qualitative interviews with patients and expert dermatologists. Adv Ther. 2020;37(2):898\u2013910. https:\/\/doi.org\/10.1007\/s12325-019-01164-5.","journal-title":"Adv Ther"},{"issue":"2","key":"2262_CR58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00403-024-02818-3","volume":"316","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Agner T, Baranowski K, et al. Validation of the investigator global assessment of chronic hand eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity. Arch Dermatol Res. 2024;316(2):161\u201371. https:\/\/doi.org\/10.1007\/s00403-024-02818-3.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"2262_CR59","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40271-019-00373-y","volume":"12","author":"A Barrett","year":"2019","unstructured":"Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient. 2019;12(5):445\u201359. https:\/\/doi.org\/10.1007\/s40271-019-00373-y.","journal-title":"Patient"},{"issue":"1","key":"2262_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13555-024-01114-2","volume":"14","author":"S Molin","year":"2024","unstructured":"Molin S, Larsen LS, Joensson P, et al. Development and psychometric validation of a patient-reported outcome measure to assess the signs and symptoms of chronic hand eczema: the Hand Eczema Symptom Diary (HESD). Dermatol Ther (Heidelb). 2024;14(1):49\u201362. https:\/\/doi.org\/10.1007\/s13555-024-01114-2.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"2262_CR61","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s13555-024-01267-0","volume":"14","author":"E Weisshaar","year":"2024","unstructured":"Weisshaar E, Y\u00fcksel YT, Agner T, Larsen LS, Grant L, Arbuckle R, et al. Development and validation of a patient-reported outcome measure of the impact of chronic hand eczema on health-related quality of life: the Hand Eczema Impact Scale (HEIS). Dermatol Ther (Heidelb). 2024;14(11):3047\u201370. https:\/\/doi.org\/10.1007\/s13555-024-01267-0.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"2262_CR62","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.12819","volume":"171","author":"RF Ofenloch","year":"2014","unstructured":"Ofenloch RF, Weisshaar E, Dumke AK, et al. The quality of life in hand eczema questionnaire (QOLHEQ): validation of the German version of a new disease-specific measure of quality of life for patients with hand eczema. Br J Dermatol. 2014;171(2):304\u201312.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2262_CR63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cod.13390","volume":"45","author":"M Tauber","year":"2020","unstructured":"Tauber M, Lourari S, B\u00e9rard E, et al. Positive change in hand care habits using therapeutic patient education in chronic hand eczema. Clin Exp Dermatol. 2020;45(2):159\u201365. https:\/\/doi.org\/10.1111\/cod.13390.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"2262_CR64","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40272-023-00574-x","volume":"25","author":"MA Haft","year":"2023","unstructured":"Haft MA, Park HH, Lee SS, et al. Diagnosis and management of pediatric chronic hand eczema: the PeDRA CACHES survey. Paediatr Drugs. 2023;25(4):459\u201366. https:\/\/doi.org\/10.1007\/s40272-023-00574-x.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"2262_CR65","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jdv.16062","volume":"34","author":"P Elsner","year":"2020","unstructured":"Elsner P. Hand eczema: treatment. J Eur Acad Dermatol Venereol. 2020;34(1):13\u20139. https:\/\/doi.org\/10.1111\/jdv.16062.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2262_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010362","volume":"25","author":"V Tancredi","year":"2023","unstructured":"Tancredi V, Buononato D, Caccavale S, Di Brizzi EV, Di Caprio R, Argenziano G, et al. New perspectives in the management of chronic hand eczema: lessons from pathogenesis. Int J Mol Sci. 2023;25(1):362. https:\/\/doi.org\/10.3390\/ijms25010362.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2262_CR67","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12840","volume":"32","author":"GR Lee","year":"2019","unstructured":"Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. https:\/\/doi.org\/10.1111\/dth.12840.","journal-title":"Dermatol Ther"},{"issue":"7","key":"2262_CR68","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/j.1468-3083.2010.03615.x","volume":"24","author":"R Bissonnette","year":"2010","unstructured":"Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24(7):825\u201337. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03615.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2262_CR69","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/00128071-200708030-00003","volume":"8","author":"U Wollina","year":"2007","unstructured":"Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol. 2007;8(3):157\u201373. https:\/\/doi.org\/10.2165\/00128071-200708030-00003.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"2262_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12956","volume":"32","author":"P Juntongjin","year":"2019","unstructured":"Juntongjin P, Pongprasert R. Calcipotriol ointment shows comparable efficacy to topical steroids in chronic hand eczema. Dermatol Ther. 2019;32(4):e12956. https:\/\/doi.org\/10.1111\/dth.12956.","journal-title":"Dermatol Ther"},{"issue":"5","key":"2262_CR71","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3892\/etm.2015.2729","volume":"10","author":"M Yang","year":"2015","unstructured":"Yang M, Chang JM. Successful treatment of refractory chronic hand eczema with calcipotriol\/betamethasone ointment: a report of three cases. Exp Ther Med. 2015;10(5):1943\u20136. https:\/\/doi.org\/10.3892\/etm.2015.2729.","journal-title":"Exp Ther Med"},{"issue":"4","key":"2262_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004055.pub2","volume":"2019","author":"WA Christoffers","year":"2019","unstructured":"Christoffers WA, Coenraads P-J, Svensson \u00c5, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019;2019(4):CD004055. https:\/\/doi.org\/10.1002\/14651858.CD004055.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2262_CR73","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/j.1398-9995.2009.02054","volume":"64","author":"C Brandt","year":"2009","unstructured":"Brandt C, Pavlovic V, Radbruch A, Worm M, Baumgrass R. Low- dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy. 2009;64(11):1588\u201396. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02054.","journal-title":"Allergy"},{"issue":"6","key":"2262_CR74","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.jaci.2014.03.003","volume":"133","author":"S Khattri","year":"2014","unstructured":"Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol. 2014;133(6):1626\u201334. https:\/\/doi.org\/10.1016\/j.jaci.2014.03.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2262_CR75","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaci.2011.03.024","volume":"128","author":"ME Schram","year":"2011","unstructured":"Schram ME, Roekevisch E, Leeflang MMG, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2011.03.024.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2262_CR76","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1525-1470.2011.01488.x","volume":"28","author":"WT Waxweiler","year":"2011","unstructured":"Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol. 2011;28(6):689\u201394. https:\/\/doi.org\/10.1111\/j.1525-1470.2011.01488.x.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"2262_CR77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2012.07.001","volume":"68","author":"M Caufield","year":"2013","unstructured":"Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2013;68(1):29\u201335. https:\/\/doi.org\/10.1016\/j.jaad.2012.07.001.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2262_CR78","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00403-025-03980-y","volume":"317","author":"A Khurana","year":"2025","unstructured":"Khurana A, Sharath S, Bansal A, et al. Baricitinib in severe and recalcitrant hyperkeratotic chronic hand eczema and associated tissue cytokine patterns: are pan JAK inhibitors a more suitable choice? Arch Dermatol Res. 2025;317(1):443. https:\/\/doi.org\/10.1007\/s00403-025-03980-y.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"2262_CR79","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","volume":"36","author":"JJ O\u2019Shea","year":"2012","unstructured":"O\u2019Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542\u201350. https:\/\/doi.org\/10.1016\/j.immuni.2012.03.014.","journal-title":"Immunity"},{"key":"2262_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106210","volume":"80","author":"P Xin","year":"2020","unstructured":"Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, et al. The role of JAK\/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210. https:\/\/doi.org\/10.1016\/j.intimp.2020.106210.","journal-title":"Int Immunopharmacol"},{"key":"2262_CR81","doi-asserted-by":"publisher","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","volume":"13","author":"IH Huang","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022;13:1068260. https:\/\/doi.org\/10.3389\/fimmu.2022.1068260.","journal-title":"Front Immunol"},{"key":"2262_CR82","doi-asserted-by":"publisher","first-page":"1110765","DOI":"10.3389\/fbioe.2023.1110765","volume":"11","author":"Q Hu","year":"2023","unstructured":"Hu Q, Bian Q, Rong D, et al. JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens. Front Bioeng Biotechnol. 2023;11:1110765. https:\/\/doi.org\/10.3389\/fbioe.2023.1110765.","journal-title":"Front Bioeng Biotechnol"},{"key":"2262_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","volume":"13","author":"H Lee","year":"2022","unstructured":"Lee H, Kim JH, Jeong H, Jang YH, Lee WJ. JAK\u2013STAT signaling pathway in the pathogenesis of atopic dermatitis. Front Immunol. 2022;13:1068260. https:\/\/doi.org\/10.3389\/fimmu.2022.1068260.","journal-title":"Front Immunol"},{"issue":"1","key":"2262_CR84","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm1162","volume":"11","author":"S Sano","year":"2005","unstructured":"Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005;11(1):43\u20139. https:\/\/doi.org\/10.1038\/nm1162.","journal-title":"Nat Med"},{"issue":"1","key":"2262_CR85","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13(1):81. https:\/\/doi.org\/10.1038\/s41419-022-04523-3.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2262_CR86","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.immuni.2015.04.014","volume":"42","author":"K Hirahara","year":"2015","unstructured":"Hirahara K, Onodera A, Villarino AV, Villarino A, Bonelli M, Scium\u00e8 G, et al. Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity. Immunity. 2015;42(5):877\u201389. https:\/\/doi.org\/10.1016\/j.immuni.2015.04.014.","journal-title":"Immunity"},{"issue":"3","key":"2262_CR87","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/ni.1995","volume":"12","author":"XP Yang","year":"2011","unstructured":"Yang XP, Ghoreschi K, Steward-Tharp SM, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol. 2011;12(3):247\u201354. https:\/\/doi.org\/10.1038\/ni.1995.","journal-title":"Nat Immunol"},{"issue":"9","key":"2262_CR88","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrm909","volume":"3","author":"DE Levy","year":"2002","unstructured":"Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651\u201362. https:\/\/doi.org\/10.1038\/nrm909.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2262_CR89","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/exd.13370","volume":"27","author":"A Tanimoto","year":"2018","unstructured":"Tanimoto A, Ogawa Y, Oki C, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents. Exp Dermatol. 2018;27(1):22\u20139. https:\/\/doi.org\/10.1111\/exd.13370.","journal-title":"Exp Dermatol"},{"issue":"8","key":"2262_CR90","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/0192623320970896","volume":"48","author":"A Anagawa-Nakamura","year":"2020","unstructured":"Anagawa-Nakamura A, Ryoke K, Yasui Y, Shoda T, Sugai S. Effects of delgocitinib ointment 0.5% on the normal mouse skin and epidermal tight junction proteins in comparison with topical corticosteroids. Toxicol Pathol. 2020;48(8):1008\u201316. https:\/\/doi.org\/10.1177\/0192623320970896.","journal-title":"Toxicol Pathol"},{"key":"2262_CR91","unstructured":"Bunick C, Schlapbach C, Erhan U, Maslin D, Sunesen VH, Pedersen GP, et al. Delgocitinib cream formulation development for chronic hand eczema (CHE): insights from patient preference and skin penetration studies [abstract no. 2785]. In: EADV Congress; 17\u201320 Sep, 2025; Paris."},{"key":"2262_CR92","unstructured":"European Medicines Agency. Anzupgo: EPAR: public assessment report. EMA\/CHMP\/238977\/2024. Published September 24, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/anzupgo-epar-public-assessment-report_en.pdf. Accessed 17 Nov 2025."},{"key":"2262_CR93","unstructured":"ClinicalTrials.gov. Proof of concept, twice daily applications of LEO 124249 ointment in the treatment of chronic hand eczema. ClinicalTrials.gov identifier: NCT02664805. Updated April 4, 2025. https:\/\/clinicaltrials.gov\/study\/NCT02664805. Accessed 24 Apr 2025."},{"issue":"5","key":"2262_CR94","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/bjd.18469","volume":"182","author":"M Worm","year":"2020","unstructured":"Worm M, Bauer A, Elsner P, Mahler V, Molin S, Nielsen TSS. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol. 2020;182(5):1103\u201310. https:\/\/doi.org\/10.1111\/bjd.18469.","journal-title":"Br J Dermatol"},{"key":"2262_CR95","unstructured":"ClinicalTrials.gov. Phase 2b dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg\/g compared to delgocitinib cream vehicle over a 16-week treatment period in adult subjects with chronic hand eczema. ClinicalTrials.gov identifier: NCT03683719. https:\/\/clinicaltrials.gov\/study\/NCT03683719. Accessed 24 Apr 2025."},{"issue":"1","key":"2262_CR96","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/bjd.21037","volume":"187","author":"M Worm","year":"2022","unstructured":"Worm M, Thyssen JP, Schliemann S, Bauer A, Shi VY, Ehst B, et al. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial. Br J Dermatol. 2022;187(1):42\u201351. https:\/\/doi.org\/10.1111\/bjd.21037.","journal-title":"Br J Dermatol"},{"issue":"6","key":"2262_CR97","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1111\/cod.14303","volume":"48","author":"A Bauer","year":"2023","unstructured":"Bauer A, Thyssen JP, Buhl T, et al. Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: results from the Hand Eczema Symptom Diary in a phase IIb randomized clinical trial. Clin Exp Dermatol. 2023;48(6):e253\u201360. https:\/\/doi.org\/10.1111\/cod.14303.","journal-title":"Clin Exp Dermatol"},{"key":"2262_CR98","unstructured":"ClinicalTrials.gov. A 24 week trial to compare the efficacy and safety of delgocitinib cream 20 mg\/g twice-daily with alitretinoin capsules once-daily in adult participants with severe chronic hand eczema. ClinicalTrials.gov identifier: NCT05259722. Updated April 24, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05259722. Accessed 24 Apr 2025."},{"issue":"10456","key":"2262_CR99","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(25)00001-7","volume":"405","author":"AM Gim\u00e9nez-Arnau","year":"2025","unstructured":"Gim\u00e9nez-Arnau AM, Pinter A, Sondermann W, et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin in adults with severe chronic hand eczema (DELTA FORCE): a multicentre, randomised, assessor-blinded, phase 3 trial. Lancet. 2025;405(10456):123\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(25)00001-7.","journal-title":"Lancet"},{"key":"2262_CR100","unstructured":"Gim\u00e9nez-Arnau AM, Pinter A, Sondermann W, et al. DELTA FORCE trial: 24-week phase 3 trial comparing the efficacy and safety of topical delgocitinib cream with oral alitretinoin capsules in adults with severe CHE [abstract #7986]. In: Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024; September 25\u201328, 2024; Amsterdam."},{"key":"2262_CR101","unstructured":"ClinicalTrials.gov. Efficacy and safety of delgocitinib cream in adolescents 12\u201317 years of age with moderate to severe chronic hand eczema (DELTA TEEN). ClinicalTrials.gov identifier: NCT05355818. Updated January 23, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05355818. Accessed 24 Apr 2025."},{"key":"2262_CR102","unstructured":"LEO Pharma. DELTA TEEN phase 3 trial of delgocitinib cream in adolescent patients with moderate-to-severe chronic hand eczema met all primary and key secondary endpoints. Published April 16, 2025. https:\/\/www.leo-pharma.com\/media-center\/news\/2025-delta-teen-topline-key-results. Accessed 17 Nov 2025."},{"key":"2262_CR103","unstructured":"ClinicalTrials.gov. A trial to evaluate efficacy, safety, and pharmacokinetics of delgocitinib cream in Chinese adults and adolescents With moderate to severe chronic hand eczema. ClinicalTrials.gov identifier: NCT06004050. Updated April 24, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06004050. Accessed 24 Apr 2025."},{"key":"2262_CR104","unstructured":"LEO Pharma. LEO Pharma meets primary endpoint in Phase 3 DELTA China trial with Anzupgo\u00ae (delgocitinib) cream in Chinese patients with moderate to severe chronic hand eczema (CHE). Published February 27, 2025. https:\/\/www.leo-pharma.com\/media-center\/news\/2025-phase-3-delta-china-trial. Accessed 17 Nov 2025."},{"key":"2262_CR105","unstructured":"LEO Pharma. LEO Pharma reports positive results in delgocitinib trial for CHE. Dermatology Times. Published April 17, 2025. https:\/\/www.dermatologytimes.com\/view\/leo-pharma-reports-positive-results-in-delgocitinib-trial-for-che. Accessed 17 Nov 2025."},{"key":"2262_CR106","unstructured":"Dermatology Times. Two major regulatory milestones announced for delgocitinib for CHE. Published September 25, 2024. https:\/\/www.dermatologytimes.com\/view\/two-major-regulatory-milestones-announced-for-delgocitinib-for-che. Accessed 21 Apr 2025."},{"key":"2262_CR107","unstructured":"National Eczema Association. FDA accepts New Drug Application for delgocitinib cream for chronic hand eczema. Published September 26, 2024. https:\/\/nationaleczema.org\/blog\/press-release-leo-pharma-delgocitinib-chronic-hand-eczema. Accessed 12 Apr 2025."},{"key":"2262_CR108","unstructured":"Japan Tobacco Inc. JT receives approvals of CORECTIM\u00ae ointment 0.25% and 0.5% for the treatment of pediatric atopic dermatitis in Japan [press release]. March 23, 2021. https:\/\/www.jt.com\/media\/news\/2021\/pdf\/20210323_E1.pdf. Accessed 17 Nov 2025."},{"issue":"2","key":"2262_CR109","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/1346-8138.15173","volume":"47","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Murata R, Kaino H, et al. Long\u2010term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2020;47(2):114\u201320. https:\/\/doi.org\/10.1111\/1346-8138.15173.","journal-title":"J Dermatol"},{"issue":"4","key":"2262_CR110","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","volume":"82","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020;82(4):823\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.015.","journal-title":"J Am Acad Dermatol"},{"key":"2262_CR111","unstructured":"Torii Pharmaceutical. Top-line results of JTE-052 ointment, JAK inhibitor, phase 3 clinical study in pediatric patients with atopic dermatitis (comparative study) in Japan [media release]. 25 Apr 2019. https:\/\/www.torii.co.jp\/en\/. Accessed 17 Nov 2025."},{"issue":"4","key":"2262_CR112","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","volume":"85","author":"H Nakagawa","year":"2021","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kabashima K, Oda M, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol. 2021;85(4):854\u201362. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.014.","journal-title":"J Am Acad Dermatol"},{"key":"2262_CR113","unstructured":"ClinicalTrials.gov. A phase 2a, randomized, double-blind, vehicle-controlled, single site, exploratory trial to assess the effect of delgocitinib cream 20 mg\/g on the molecular signature, safety, and efficacy in adults with frontal fibrosing alopecia. Identifier: NCT05332366. https:\/\/clinicaltrials.gov\/study\/NCT05332366. Accessed 17 Nov 2025."},{"key":"2262_CR114","unstructured":"Senna MM, Carnahan J, Wenzke L, Mesinkovska NA, Paus R, Sadick N, et al. Randomized vehicle-controlled clinical trial with the topical JAK inhibitor delgocitinib in patients with frontal fibrosing alopecia demonstrates biomarker and clinical efficacy [abstract]. In: Presented at: 33rd European Academy of Dermatology and Venereology (EADV) Congress; 2024 Sep 25\u201328; Amsterdam."},{"key":"2262_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.09.375","author":"A Martin","year":"2025","unstructured":"Martin A, Shokrian N, Kelley KJ, da Rosa JC, Del-Duca E, Bissonnette R, et al. Randomized controlled trial of the topical JAK inhibitor delgocitinib cream in patients with frontal fibrosing alopecia. J Invest Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jid.2025.09.375.","journal-title":"J Invest Dermatol"},{"key":"2262_CR116","unstructured":"ClinicalTrials.gov. LEO 124249 ointment in the treatment of alopecia reata. NCT02561585. https:\/\/clinicaltrials.gov\/study\/NCT02561585. Accessed 17 Nov 2025."},{"issue":"2","key":"2262_CR117","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00403-022-02336-0","volume":"315","author":"D Mikhaylov","year":"2023","unstructured":"Mikhaylov D, Glickman JW, Del Duca E, et al. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2023;315(2):181\u20139. https:\/\/doi.org\/10.1007\/s00403-022-02336-0.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"2262_CR118","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19429","volume":"38","author":"A Senda","year":"2024","unstructured":"Senda A, Shibuya R, Miyake T, Nomura T, Dainichi T, Kabashima K. Alopecia areata in a patient with cytotoxic T lymphocyte antigen-4 haploinsufficiency successfully treated with topical delgocitinib ointment. J Eur Acad Dermatol Venereol. 2024;38(1):e51. https:\/\/doi.org\/10.1111\/jdv.19429.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2262_CR119","unstructured":"ClinicalTrials.gov. Efficacy and safety of delgocitinib cream in discoid lupus erythematosus. ClinicalTrials.gov identifier: NCT03958955. Updated February 2, 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03958955. Accessed 24 Apr 2025."},{"issue":"3","key":"2262_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16639","volume":"50","author":"A Maruyama","year":"2023","unstructured":"Maruyama A, Katoh N. Subacute cutaneous lupus erythematosus successfully treated with topical delgocitinib. J Dermatol. 2023;50(3):e110. https:\/\/doi.org\/10.1111\/1346-8138.16639.","journal-title":"J Dermatol"},{"issue":"11","key":"2262_CR121","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1111\/jdv.19162","volume":"37","author":"G Tavoletti","year":"2023","unstructured":"Tavoletti G, Avallone G, Conforti C, Roccuzzo G, Maronese CA, Mattioli MA, et al. Topical ruxolitinib: a new treatment for vitiligo. J Eur Acad Dermatol Venereol. 2023;37(11):2222\u201330. https:\/\/doi.org\/10.1111\/jdv.19162.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"2262_CR122","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/ijd.17157","volume":"63","author":"A Utama","year":"2024","unstructured":"Utama A, Wijesinghe R, Thng S. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review. Int J Dermatol. 2024;63(8):1020\u201335. https:\/\/doi.org\/10.1111\/ijd.17157.","journal-title":"Int J Dermatol"},{"issue":"4","key":"2262_CR123","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1111\/ajd.13572","volume":"62","author":"M Kim","year":"2021","unstructured":"Kim M, Kim S, Park H, et al. Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib. Australas J Dermatol. 2021;62(4):e540\u20132. https:\/\/doi.org\/10.1111\/ajd.13572.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"2262_CR124","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17151","volume":"51","author":"J Asai","year":"2024","unstructured":"Asai J, Ohta R, Maruyama A, Katoh N. Lichen planus pigmentosus successfully treated with topical delgocitinib. J Dermatol. 2024;51(5):e187. https:\/\/doi.org\/10.1111\/1346-8138.17151.","journal-title":"J Dermatol"},{"issue":"6","key":"2262_CR125","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15844","volume":"41","author":"M Yamamoto","year":"2024","unstructured":"Yamamoto M, Nakajima K, Matsuda M, Takahashi A, Nakai K. Benefits of the topical JAK inhibitor delgocitinib in a patient with pediatric localized scleroderma. Pediatr Dermatol. 2024;41(6):e123. https:\/\/doi.org\/10.1111\/pde.15844.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"2262_CR126","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15437","volume":"35","author":"S McGaugh","year":"2022","unstructured":"McGaugh S, Kallis P, De Benedetto A, Thomas RM. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: a literature review. Dermatol Ther. 2022;35(6):e15437. https:\/\/doi.org\/10.1111\/dth.15437.","journal-title":"Dermatol Ther"},{"issue":"3","key":"2262_CR127","doi-asserted-by":"publisher","first-page":"188","DOI":"10.36849\/jdd.7696","volume":"23","author":"MP Zundell","year":"2024","unstructured":"Zundell MP, Al-Dehneem R, Song T, Yousif J, Gottlieb AB. Novel clinical applications of topical ruxolitinib: a case series. J Drugs Dermatol. 2024;23(3):188\u201390. https:\/\/doi.org\/10.36849\/jdd.7696.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"2262_CR128","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1177\/12034754241260021","volume":"28","author":"H Rijal","year":"2024","unstructured":"Rijal H, Bouadi N, Piguet V, Mukovozov I. Treatment outcomes of scleroderma with Janus kinase inhibitors: a systematic review. J Cutan Med Surg. 2024;28(5):489\u201390. https:\/\/doi.org\/10.1177\/12034754241260021.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"2262_CR129","doi-asserted-by":"publisher","first-page":"747","DOI":"10.25251\/skin.7.2.19","volume":"7","author":"MA Dirr","year":"2023","unstructured":"Dirr MA, Bailey AM, Marchell R. Successful treatment of morphea with topical ruxolitinib. Skin J Cutan Med. 2023;7(2):747\u20139. https:\/\/doi.org\/10.25251\/skin.7.2.19.","journal-title":"Skin J Cutan Med"},{"issue":"11","key":"2262_CR130","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/ijd.17239","volume":"63","author":"D Hoshina","year":"2024","unstructured":"Hoshina D, Kimura A. Cutaneous T-cell pseudolymphoma successfully treated with topical delgocitinib. Int J Dermatol. 2024;63(11):1610\u20131. https:\/\/doi.org\/10.1111\/ijd.17239.","journal-title":"Int J Dermatol"},{"issue":"2","key":"2262_CR131","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14888","volume":"34","author":"T Miyagaki","year":"2021","unstructured":"Miyagaki T, Okano T, Nakajima K, Mitsuishi S, Kishi A, Miyano K, et al. A case of facial redness in atopic dermatitis occurring during dupilumab treatment successfully treated with topical delgocitinib ointment. Dermatol Ther. 2021;34(2):e14888. https:\/\/doi.org\/10.1111\/dth.14888.","journal-title":"Dermatol Ther"},{"issue":"7","key":"2262_CR132","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1111\/1346-8138.15897","volume":"48","author":"Y Muto","year":"2021","unstructured":"Muto Y, Mitsui H, Ogawa Y, Deguchi N, Shimada S, Kawamura T. Case of cutaneous sarcoidosis treated with delgocitinib 0.5% ointment. J Dermatol. 2021;48(7):e322\u20133. https:\/\/doi.org\/10.1111\/1346-8138.15897.","journal-title":"J Dermatol"},{"key":"2262_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdcr.2020.12.021","volume":"9","author":"M Alam","year":"2021","unstructured":"Alam M, Fang V, Rosenbach M. Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil. JAAD Case Rep. 2021;9:1\u20133. https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.021.","journal-title":"JAAD Case Rep"},{"issue":"11","key":"2262_CR134","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17311","volume":"51","author":"M Teraoka","year":"2024","unstructured":"Teraoka M, Yonekura S, Takegami T, Murata T, Egawa G, Nakajima S, et al. Effective treatment of topical corticosteroid-resistant dermatitis with delgocitinib in a pediatric patient with Netherton syndrome. J Dermatol. 2024;51(11):e395. https:\/\/doi.org\/10.1111\/1346-8138.17311.","journal-title":"J Dermatol"},{"key":"2262_CR135","unstructured":"ClinicalTrials.gov. Clinical trial to evaluate light-induced skin reactions after application of delgocitinib cream. Identifier: NCT04361136. https:\/\/clinicaltrials.gov\/study\/NCT04361136. Accessed 17 Nov 2025."},{"key":"2262_CR136","unstructured":"ClinicalTrials.gov. Clinical trial to evaluate UV-light-induced allergic skin reactions after application of delgocitinib cream. Identifier: NCT04807751. https:\/\/clinicaltrials.gov\/study\/NCT04807751. Accessed 17 Nov 2025."},{"issue":"5","key":"2262_CR137","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaad.2024.01.004","volume":"90","author":"G Avallone","year":"2024","unstructured":"Avallone G, Mastorino L, Tavoletti G, et al. Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: a multicenter retrospective study. J Am Acad Dermatol. 2024;90(5):1031\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2024.01.004.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2262_CR138","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01243-8","volume":"14","author":"MG Kirchhof","year":"2024","unstructured":"Kirchhof MG, Prajapati VH, Gooderham M, Hong C-h, Lynde CW, Maari C, et al. Practical recommendations on laboratory monitoring in patients with atopic dermatitis on oral JAK inhibitors. Dermatol Ther (Heidelb). 2024;14(1):e01243. https:\/\/doi.org\/10.1007\/s13555-024-01243-8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"2262_CR139","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","volume":"160","author":"JP Ingrassia","year":"2024","unstructured":"Ingrassia JP, Maqsood MH, Gelfand JM, et al. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 2024;160(1):28\u201336. https:\/\/doi.org\/10.1001\/jamadermatol.2023.4090.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2262_CR140","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/jvc2.379","volume":"3","author":"A Lo","year":"2024","unstructured":"Lo A, Lovell KK, Greenzaid JD, Oscherwitz ME, Feldman SR. Adherence to treatment in dermatology: literature review. JEADV Clin Pract. 2024;3(2):401\u201318. https:\/\/doi.org\/10.1002\/jvc2.379.","journal-title":"JEADV Clin Pract"},{"key":"2262_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00091","volume":"4","author":"P Kardas","year":"2013","unstructured":"Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91. https:\/\/doi.org\/10.3389\/fphar.2013.00091.","journal-title":"Front Pharmacol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02262-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T02:00:19Z","timestamp":1768356019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02262-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2262"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02262-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Angelo Valerio Marzano reports consultancy\/advisory boards disease-relevant honoraria from AbbVie, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Incyte, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB. Silvia Mariel Ferrucci has conflicts of interest with Amgen, Sanofi, Novartis, Lilly, LEO Pharma, AbbVie, and Menarini. Davide Termini, Gianluca Avallone, Gianluca Tavoletti, Jessica Beaziz, Chiara Moltrasio, and Veronica Boero have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no new data were created or analyzed in this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the conceptualization, review, editing, and supervision of this manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}